Sheldon Kong, Ph.D. is Head of Research Strategy in Data Generation and Observational Studies in U.S. Medical Affairs at Bayer Pharmaceuticals. His team is responsible for U.S. research strategy in Data Generation and Observational Studies across the entire pharmaceutical portfolio.
Prior to Bayer, he was with Novo Nordisk Inc. for over six years, with four years as the Department Head of U.S. Health Economics and Outcomes Research and two years as Executive Director, Clinical Development and Outcomes Research. Before joining Novo Nordisk, he was the Department Head of Global Health Outcomes at Merck leading a team of health economists, epidemiologists, health service researchers, physicians, pharmacists and statisticians to develop strategy and evidence to support the global value proposition of its pharmaceuticals and vaccines. He was Assistant Professor of Pharmacy Administration at the University of Illinois at Chicago where he taught graduate level Pharmacoeconomics and Advanced Research Methods before joining the pharmaceutical industry and today still holds the appointment of Adjunct Professor of Pharmacy Systems, Outcomes and Policy. He also holds the appointment of Adjunct Professor and Corporate HEOR Advisory Board member at the Rutgers University Ernest Mario School of Pharmacy. He currently serves as a member of the HEOR Corporate Advisory Board of College of Pharmacy, University of Washington in Seattle.